AMES, IA-- January 6, 2014 - NewLink Genetics Corporation (NASDAQ: NLNK), a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutics to improve treatment options for patients with cancer, announced today that Charles J. Link, Jr., M.D., NewLink's Founder and Chief Executive Officer, is scheduled to present at the 32nd Annual JP Morgan Healthcare Conference in San Francisco, on Wednesday, January 15, 2014 at 10:00 a.m. PT. Interested parties may access a live webcast of the presentation by visiting the NewLink Genetics website at www.linkp.com. The webcast will be archived on the NewLink website following the event.
About NewLink Genetics Corporation
NewLink is a biopharmaceutical company focused on discovering, developing and commercializing novel immunotherapeutic products to improve treatment options for patients with cancer. NewLink's portfolio includes biologic and small molecule immunotherapy product candidates intended to treat a wide range of oncology indications. NewLink's product candidates are designed to harness multiple components of the immune system to combat cancer without significant incremental toxicity, either as a monotherapy or in combination with other treatment regimens. For more information please visit http://www.linkp.com.
Contact InformationGordon LinkChief Financial Officer515firstname.lastname@example.org
SOURCE: NewLink Genetics Corporation